Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

77TiP - A phase I/II dose escalation and dose expansion study of ozuriftamab vedotin (BA3021) alone and in combination with nivolumab in patients with advanced solid tumors including non-small cell lung cancer


31 Mar 2023


Poster Display session


Mariam Alexander


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


M. Alexander1, A. Starodub2

Author affiliations

  • 1 MUSC Health University Medical Center, Mount Pleasant/US
  • 2 The Christ Hospital - Hematology & Oncology, Cincinnati/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 77TiP


Ozuriftamab vedotin (BA3021) is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody (IgG1) conjugated to monomethyl auristatin E (MMAE) using a cleavable linker (CAB ROR2 ADC). Preclinical data suggest targeting ROR2 may result in antitumor activities in various tumor types, such as NSCLC. Taken together with the proposed mechanism of BA3021 and underlying biology, antitumor activity in NSCLC is anticipated. The upregulation of ROR2 in PD-1 resistant tumor strongly suggests its role in resistance and recurrence in this population.

Trial design

BA3021-001 is a multi-center, open-label, phase I/II study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors. Phase I will comprise 2 sequential parts—dose escalation and dose expansion—and is designed to evaluate the safety and tolerability of BA3021 in patients with advanced solid tumors and to identify the MTD and/or RP2D for BA3021. Phase II is an open-label study to evaluate the efficacy and safety of BA3021 alone and in combination with nivolumab in patients with ROR2-expressing tumor membrane percent score ≥ 1%, metastatic NSCLC, or melanoma who have measurable disease by RECIST version 1.1 criteria and have documented progression according to RECIST v1.1 criteria within the 6 months prior to enrollment. NSCLC patients must have experienced failure, defined as disease progression or discontinuation due to an adverse event, of a PD-1/L-1, epidermal growth factor receptor (EGFR) inhibitor, or anaplastic lymphoma kinase (ALK) inhibitor (either monotherapy or in combination with another therapy such as ipilimumab). Enrollment completion is anticipated in 2023.

Clinical trial identification

NCT04681131; EudraCT 2022-000135-23.

Legal entity responsible for the study

BioAtla, Inc.


BioAtla, Inc.


M. Alexander: Financial Interests, Personal, Principal Investigator: BioAtla. A. Starodub: Financial Interests, Personal, Principal Investigator: BioAtla.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.